Lipohypertrophy
Lipohypertrophy is thick fat under the skin. It forms in a spot where shots go in again and again. Insulin labels call it "thickening of adipose tissue." Adipose tissue is fat. Patient leaflets call it thickened skin.
Paste this code into your page. It shows the sub q injection sites body map with one plain credit link.
Learn
What the labels say it is
The Humalog label says lipodystrophy "includes lipohypertrophy (thickening of adipose tissue) and lipoatrophy (thinning of adipose tissue)." The Lantus label calls lipohypertrophy "enlargement or thickening of tissue."
The patient leaflets use plain words. They call lipodystrophy "pits in skin or thickened skin." They also name a second problem. Its long name is localized cutaneous amyloidosis. The leaflets call it "skin with lumps." Both can form where you inject.
How common it is
A 2018 review (Deng and others) pooled 26 studies. They had 12,493 people who inject insulin. About 38 percent had lipohypertrophy. The likely range was 29 to 46 percent. It was more common in type 2 diabetes (49 percent) than in type 1 (34 percent).
Most of these studies found it by looking at and feeling the skin where shots go. The review says scans and tissue tests can find it too. But they cost more time or money.
Why it matters
A group of 183 diabetes experts (Frid and others, 2016) wrote about it. They said it is common and that it "distorts insulin absorption." That means the body may take in the insulin in a different way. The Humalog label says lipodystrophy "may affect insulin absorption."
The insulin labels also report two things about blood sugar:
- Repeated insulin shots into these areas have been reported to cause high blood sugar.
- A sudden change to an unaffected area has been reported to cause low blood sugar.
The labels tell doctors what to say to people who have been injecting into these areas. They should move to skin that is not affected. And they should watch closely for low blood sugar. So if you find a lump, talk to your care team before you change where you inject.
How the sources say to lower the risk
- Rotate. Insulin labels say to rotate within the same region from one shot to the next. They say this lowers the risk of both problems. The Frid group says correct rotation helps prevent lipohypertrophy.
- Space your shots. MedlinePlus says to move at least 1 inch (2.5 cm) from one injection to the next.
- Skip lumps. The labels say: "Do not inject into areas of lipodystrophy or localized cutaneous amyloidosis."
The printable rotation sheet helps you keep track of areas, and the step by step injection guide shows how to check a spot first. The sub q injection sites body map shows the areas, and the Zepbound and Mounjaro page shows that some GLP-1 leaflets use the same rotation words.
Questions
What causes lipohypertrophy?
It forms at injection sites used again and again. The Humalog label says long term use of insulin can cause lipodystrophy at the site of repeated insulin injections. The Frid group says correct site rotation helps prevent it.
What does lipohypertrophy look like?
Patient leaflets describe it as thickened skin. The labels define it as thick fat tissue. In the 2018 review, most studies found it by looking at and feeling the skin where shots go.
What is the difference between lipohypertrophy and lipodystrophy?
Lipodystrophy is the wider term. The Humalog label says it includes lipohypertrophy, which is thickening of the fat, and lipoatrophy, which is thinning of the fat. Patient leaflets call these pits in skin or thickened skin.
What happens if you don't rotate insulin injection sites?
The labels say rotating lowers the risk of pits, thick skin and lumps. They also report high blood sugar after repeated shots into those areas. If you find a lump, ask your care team before you change areas.
Sources
5 sources with read dates
- Humalog label, sections 2.2, 5 and 6, Patient Package Insert and Instructions for Use leaflets, DailyMed, US National Library of Medicine, v87 (June 16, 2026), read 2026-10-06
- Lantus label, sections 2, 5 and 6, DailyMed, v35 (June 2, 2025), read 2026-10-06
- Deng N and others, Prevalence of lipohypertrophy in insulin-treated diabetes patients: a systematic review and meta-analysis, Journal of Diabetes Investigation 2018;9(3):536, doi:10.1111/jdi.12742, PMID 28862814, full text read on PMC (PMC5934253), read 2026-10-06
- Frid AH and others, New Insulin Delivery Recommendations, Mayo Clinic Proceedings 2016;91(9):1231 to 1255, doi:10.1016/j.mayocp.2016.06.010, PMID 27594187 (abstract), read 2026-10-06
- Subcutaneous (SQ) injections, MedlinePlus, US National Library of Medicine, reviewed October 19, 2025, read 2026-10-06